[HTML][HTML] Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
X Wang, L Sima - 2022 - europepmc.org
Objectives Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus
constitute an important preventive option against coronavirus disease 2019 (COVID-19) …
constitute an important preventive option against coronavirus disease 2019 (COVID-19) …
Longitudinal humoral and cellular immune responses following SARS-CoV-2 vaccination in patients with myeloid and lymphoid neoplasms compared to a reference …
S Jotschke, S Schulze, N Jaekel, B Ludwig-Kraus… - Cancers, 2022 - mdpi.com
Simple Summary The kinetics of SARS-CoV-2 spike-protein antibodies and the cellular
immune landscape following vaccination in patients with hematologic neoplasms are poorly …
immune landscape following vaccination in patients with hematologic neoplasms are poorly …
[HTML][HTML] Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
C Tandler, JS Heitmann, TM Michel… - International Journal of …, 2024 - Elsevier
Objectives T cell immunity is key for the control of viral infections including SARS-CoV-2, in
particular with regard to immune memory and protection against arising genetic variants …
particular with regard to immune memory and protection against arising genetic variants …
Anti-spike antibody response to the COVID vaccine in lymphoma patients
A Della Pia, GY Kim, A Ip, J Ahn, Y Liu, S Kats… - Plos one, 2022 - journals.plos.org
Patients with hematologic malignancies have poor outcomes from COVID infection and are
less likely to mount an antibody response after COVID infection. This is a retrospective study …
less likely to mount an antibody response after COVID infection. This is a retrospective study …
Vaccinations in Patient with Chronic Lymphocytic Leukemia
ER Francis, J Vu, CO Perez, C Sun - Seminars in Hematology, 2024 - Elsevier
Chronic lymphocytic leukemia (CLL) is characterized by immune dysfunction resulting in
heightened susceptibility to infections and elevated rates of morbidity and mortality. A key …
heightened susceptibility to infections and elevated rates of morbidity and mortality. A key …
[HTML][HTML] Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
HM Ingelman-Sundberg, L Blixt, D Wullimann… - …, 2024 - ncbi.nlm.nih.gov
The COVID-19 pandemic has significantly impacted patients with chronic lymphocytic
leukemia (CLL), 1 with many failing to seroconvert2 or mediate variable T-cell immunity3 …
leukemia (CLL), 1 with many failing to seroconvert2 or mediate variable T-cell immunity3 …
Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience
C Baratè, T Caruso, F Mavilia, P Sammuri… - Clinical and …, 2023 - Springer
Vaccination represents the best strategy to fight COVID-19 pandemics, especially in immune
compromised subjects. In chronic lymphatic leukemia patients, a marked impairment of the …
compromised subjects. In chronic lymphatic leukemia patients, a marked impairment of the …
IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
H Xie, J Zhang, R Luo, Y Qi, Y Lin, C Han, X Li… - BMC immunology, 2024 - Springer
Background The ability of generating effective humoral immune responses to SARS-CoV-2
infection has not been clarified in lymphoma patients. The study aimed to investigate the …
infection has not been clarified in lymphoma patients. The study aimed to investigate the …
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: Ibrutinib-associated adverse events and their management based on drug …
HJ Cho, DW Baek, J Kim, JM Lee… - Expert Review of …, 2021 - Taylor & Francis
Introduction Ibrutinib is a highly effective drug for patients with chronic lymphocytic leukemia
(CLL), and is well tolerated even by older patients and those unfit to receive conventional …
(CLL), and is well tolerated even by older patients and those unfit to receive conventional …
The Trajectory of the COVID-19 Vaccine Antibody Titers Over Time and the Association of Mycophenolate Mofetil in Solid Organ Transplant Recipients
A Sakai, T Morishita, K Suzumura, F Hanatate… - Transplantation …, 2022 - Elsevier
The COVID-19 vaccine will be safe and effective in solid organ transplant recipients (SOTs).
However, the blunted antibody responses were also of concern. Few studies have reported …
However, the blunted antibody responses were also of concern. Few studies have reported …